Bio-Techne and Elpiscience partner on therapeutic antibody R&D

Bio-Techne Corporation and Elpiscience BioPharma are to strategically collaborate on the development of novel cancer immunotherapies. Elpiscience will have access to multiple antibodies from Bio-Techne’s product portfolio to develop preclinical, clinical, and commercial biopharmaceuticals. This partnership will expand mutual capabilities in the field of cancer immunotherapy, and aims to fast-track the development of new biologics to tackle the medical gaps in oncology.
President of Bio-Techne’s Protein Sciences Segment, David Eansor, said: “We are extremely excited to partner with Elpiscience for the development of novel cancer immunotherapies. It is our goal to increase our partnerships with developers of therapeutics in order to unleash the potential of our vast library of high-quality antibodies towards the development of next generation immunotherapies.”
Elpiscience chief executive officer, Dr. Darren Ji, said: “We are very happy to enter into a strategic collaboration with Bio-Techne in therapeutic antibody research and development. This collaboration will leverage the strengths of both companies in the field of anti-cancer therapeutics and speed up the development of new cancer immunotherapies in order to bring more efficient treatment to cancer patients worldwide.”